"This year has been a major turning point in American health care," reports USA Today, "and patients can anticipate several major developments in the new year," including the beginning of a CRISPR "revolution" and "a new reckoning with drug prices that could change the landscape of the U.S. health care system for decades to come." Health care officials expect 2024 to bring a wave of innovation and change in medicine, treatment and public health... Many think 2024 could be the year more people have the tools to follow through on New Year's resolutions about weight loss. If they can afford them and manage to stick with them, people can turn to a new generation of remarkably effective weight-loss drugs, also called GLP-1s, which offer the potential for substantial weight loss...

In 2023, mental health issues became among the nation's most deadly, costly and pervasive health crises... The dearth of remedies has also paved the way for an unsuspecting class of drugs: psychedelics. MDMA, a party drug commonly known as "ecstasy," could win approval for legal distribution in 2024, as a treatment for post-traumatic stress disorder. Another psychedelic, a ketamine derivative eskatemine, sold as Spravato, was approved in 2019 to treat depression, but it is being treated like a conventional therapy that must be dosed regularly, not like a psychedelic that provides a long-lasting learning experience, said Matthew Johnson, an expert in psychedelics at Johns Hopkins University. MDMA (midomafetamine capsules) would be different, as the first true psychedelic to win FDA approval.

In a late-stage trial of patients with moderate or severe post-traumatic stress disorder, close to 90% showed clinically significant improvements four months after three treatments with MDMA and more than 70% no longer met the criteria for having the disorder, which represented "really impressive results," according to Matthew Johnson, an expert in psychedelics at Johns Hopkins University in Maryland. Psilocybin, known colloquially as "magic mushrooms," is also working its way through the federal approval process, but it likely won't come up before officials for another year, Johnson said. Psychedelics are something to keep an eye on in the future, as they're being used to treat an array of mental health issues: eskatimine for depression, MDMA for PTSD and psilocybin for addiction. Johnson said his research suggests that psychedelics will probably have a generalizable benefit across many mental health challenges in the years to come.

2024 will also be the first year America's drug-makers face new limits on how much they can increase prices for drugs covered by the federal health insurance program Medicare.